Publications by authors named "Anna Frustaci"

Claim this Profile
C
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.
Ernesto Vigna, Enrica Antonia Martino, Annalisa Pitino, Raffaella Pasquale, Isacco Ferrarini, Anna Maria Frustaci

Hematol Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Alessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, Giorgio Minotti

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Alessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, Giorgio Minotti

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Anna Maria Frustaci

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.
Alberto Fresa, Idanna Innocenti, Annamaria Tomasso, Candida Vitale, Alessandro Sanna, Anna Maria Frustaci

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Alessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, Giorgio Minotti

Leukemia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).
Luca De Carolis, Monia Capponi, Andrea Bernardelli, Andrea Visentin, Gianna Maria D'Elia, Anna Maria Frustaci

Hemasphere· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing-Neel Syndrome.
Anna Maria Frustaci, Arianna Zappaterra, Gloria Turri, Valentina Rossi, Marina Deodato

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.
Sara Pepe, Candida Vitale, Diana Giannarelli, Andrea Visentin, Alessandro Sanna, Anna Maria Frustaci

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.
Andrea Serafin, Alessandro Cellini, Enrica Antonia Martino, Federica Mazzetto, Francesco Angotzi, Anna Maria Frustaci

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
Adam S Kittai, Monia Marchetti, Othman Al-Sawaf, Ohad Benjamini, Alexey V Danilov, Anna Maria Frustaci

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia.
Jonas Paludo, Jithma P Abeykoon, Nirosha D Perera, Shayna Sarosiek, Joshua Gustine, Anna Maria Frustaci

Am J Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice.
Anna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, Lorena Appio, Jacopo Olivieri

Haematologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
Francesca Perutelli, Elia Boccellato, Maria Chiara Montalbano, Gioacchino Catania, Marina Deodato, Anna Maria Frustaci

Br J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triplets: the bright and the dark side of the moon.
Anna Maria Frustaci, Alessandra Tedeschi

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia.
Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, Andrea Visentin, Michele Merli

Hemasphere· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection.
Giovanna Travi, Francesco Peracchi, Marco Merli, Emanuele Ravano, Anna Frustaci

Infect Dis Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.
Idanna Innocenti, Annamaria Tomasso, Diana Giannarelli, Lydia Scarfò, Roberta Murru, Anna Maria Frustaci

Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
Marina Deodato, Anna Maria Frustaci, Arianna Zappaterra, Alberto Rapella, Carlo Gambacorti-Passerini

Leuk Lymphoma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors.
Francesca R Mauro, Anna Maria Frustaci, Andrea Visentin, Candida Vitale, Michele Bartoletti

Crit Rev Oncol Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines.
Malgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, Michele Bartoletti, Anna Maria Frustaci

Blood Rev· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.
Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda

Hemasphere· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study.
Francesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, Andrea Visentin, Anna M Frustaci

Cancers (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.
Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Marco Montillo

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis